We are motivated by a strong and sincere willingness to drive continuous improvement and renewal within ADME/PK science. We believe that a technology shift and significant quality improvements are within reach. Together we form a group of highly merited scientists with a long experience from the pharmaceutical industry, university and IT-development.
ADME/PK-prediction software with predictive power
Our software ANDROMEDA by Prosilico produces high quality in silico estimates of human clinical ADME/PK of modern drug candidates (for which standard laboratory methods have limited applicability) at a low cost. Our approach is firmly based on the assumption that clinical data is the best and most relevant source of human ADME/PK information.
The software has been carefully validated in a multitude of ways. We have also performed successful benchmarking vs alternative methods (in vitro and animal models). Median prediction errors are generally within 2- to 3-fold. Scientific publications and White paper are available to support our claims.
Make you feel good about it
You can rely on the fact that the human clinical ADME/PK parameters you get are the result of validated and relevant methods. The predictive power increases the likelihood that your compounds will have the desired ADME/PK properties in man and that clinical studies will be safe and planned for success. As a bonus you will also help to avoid unnecessary experiments in animals and reduce environmental emissions.
The latest news and publications
PROSILICO attended IDDST in Tokyo and presented new results
PROSILICO attended IDDST in Tokyo 8-10 May and gave an oral presentation of new ANDROMEDA…
